COVID-19 & Solid Tumors: Module 1 – Lung Tumors Expert Round Table

COVID-19 & Solid Tumors: Module 1 – Lung Tumors Expert Round Table

On-Demand Webcast

Corey J. Langer, MD – Moderator
Director of Thoracic Oncology
Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania.

Michael P. Angarone, DO
Infectious Disease Specialist
Northwestern Medicine
Feinberg School of Medicine
Chicago, Illinois

Marina Garassino, MD
Medical Consultant Thoracic Oncology
Medical Oncology Division
National Cancer Institute of Milan
Milan, Italy

Andrew R. Haas, MD, PhD
Director, Section of Interventional Pulmonology and Thoracic Oncology
Bronchoscopy Director
Associate Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director for Translational Research
Yale Cancer Center
New Haven, Connecticut


Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email


This activity is intended for clinicians who encounter patients with lung and GI malignancies, including medical, radiation, and surgical oncologists; and other HCPs, such as internists/hospitalists, infectious disease specialists, pulmonologists, critical care specialists, medical students, oncology nurses, nurse practitioners, physician assistants, and pharmacists working as part of the multidisciplinary oncology team during the COVID-19 pandemic.


After participating in this activity, participants should be better able to:

  • Describe up-to-the-minute developments in the epidemiology, pathology, and current treatment approaches of/for COVID-19
  • Develop risk-mitigation strategies to limit patient and provider exposure to SARS-CoV-2 without compromising effective diagnostic and therapeutic management of cancer
  • Evaluate the interplay between solid tumors and COVID-19 in terms of susceptibility to SARS-CoV- 2 and, in case of infection, effects of severity of COVID-19 and tumor progression
  • Identify, mitigate, and manage current and prospective diagnostic, therapeutic, and monitoring challenges in oncology care due to the reallocation of health resources as a result of the COVID- 19 pandemic

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: June 24, 2020
Expiration Date: June 24, 2021
Estimated Time to Complete: 1 hour

There is no fee associated with this activity.


This program is supported through educational grants from Merck Sharp & Dohme Corp, and Pfizer, Inc.


 In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this internet enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This internet enduring, knowledge-based activity (Universal Activity Number JA0006201-0000-20-132-H01-P has been approved for a maximum of 1.0 contact hour (.01 CEU).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is 60 DAYS AFTER ACTIVITY. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.


This continuing nursing education activity awards 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Chris Bolwell, Samantha Conforti, Amanda Mulder, Randy Robbin, and Margie Stefan. 

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

The faculty has reported the following:

Dr. Langer: Grant/Research Support — Advantagene, Ariad (Takada), Clovis, Genentech, GSK, Guardant Health, Inovio, Lilly, Merck, Nektar, OSI (Astelas), Pfizer, StemCentrx (Takai); Advisor—  Abbott, AbbVie, Ariad (Takada), AstraZeneca, Bayer/Onyx, Biodesix, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Clarient, Caris Dx, Clovis, Giliad, Helsinn, Hospira, Lilly, Merck, Morphotek, Novartis, Pfizer, Regeneron, Roche/Genentech, Synta, Takai, Vertex; DSMC—  Agennix, Amgen, Incyte, Lilly, Peregrine, Synta, SWOG

Dr. Garassino: Grants— Astra Zeneca; Bayer, Blueprint Medicine, BMS, Celgene, Clovis, Eli Lilly, EXELISIS, GlaxoSmithKline S.p.A, Incyte, IPSEN, MedImmune, Merck KGaA, Merck Serono, MSD, Novartis, Otsuka Pharma, Pfizer, Roche, Spectrum Pharmaceutcials, Tiziana Sciences, UNITED THERAPEUTICS CORPORATION; Personal Fees—Astra Zeneca, Bayer, Blueprint Medicine, BMS, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline S.p.A, Incyte, Inivata, Jannesen, MSD, Novartis, Otsuka Pharma, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, Spectrum Pharmaceutcials, Takeda, UNITED THERAPEUTICS CORPORATION; Resarch Grants— TURNING POINT

Dr. Haas: Consultant—Olympus America, Inc.

Dr. Herbst: Board Member—Junshi Pharmaceuticals; Consultant—Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa Consulting, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen; Research Support— AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company 

Dr. Angarone has disclosed no relevant financial relationships with any commercial interests.


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.